Track Biodesix, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Biodesix, Inc. BDSX · Stock Open Biodesix, Inc. in new tab

9.88 USD
EPS
-2.69
P/B
12.59
ROE
-778.89
Beta
0.63
Target Price
32.17 USD
Biodesix, Inc. logo

Biodesix, Inc.

🧾 Earnings Recap – Q3 2025

Biodesix reported strong third-quarter results for 2025, achieving a 20% increase in revenue and improved gross margins, while laying the groundwork for future growth in personalized diagnostics.

  • Revenue growth accelerated to 20% year-over-year, indicating robust demand for diagnostic tests.
  • Gross margins improved by 400 basis points to 81%, reflecting operational effectiveness.
  • Adjusted EBITDA enhanced by 18%, signaling progress towards profitability in Q4.
  • Tests ordered from primary care surged 75% YOY, as the company expands its market strategy to enhance lung cancer diagnostics.
  • Average revenue per test increased by 7% from Q2, supported by successful market access initiatives.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
EPS-2.69
Book Value0.79
Price to Book12.59
Debt/Equity835.04
% Insiders38.203%
Growth
Revenue Growth0.10%
Estimates
Forward P/E-44.91
Forward EPS-0.22
Target Mean Price32.17

DCF valuation

Model fair value for Biodesix, Inc. (BDSX)
Result
Sign in to run the valuation for BDSX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus Strong buy · mean target 32.17 USD (low 30.00, high 35.00) · as of 15 Nov 2026
Low 30.00
Mean 32.17
High 35.00
Price 9.88
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Biodesix, Inc. Logo Biodesix, Inc. Analysis (BDSX)

United States Health Care Official Website Stock

Is Biodesix, Inc. a good investment? Biodesix, Inc. (BDSX) is currently trading at 9.88 USD. Market analysts have a consensus price target of 32.17 USD. This suggests a potential upside from current levels.

Earnings Schedule: Biodesix, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is -0.22.

Investor FAQ

Does Biodesix, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Biodesix, Inc.?

Biodesix, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of -2.69.

Company Profile

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Exchange Ticker
NGM (Sweden) BDSX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Sept. 15, 2025 1:20
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion